R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.
Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/news-press
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Main sponsor Schüco thrilled by sporting success - Schüco dresses Germany's tallest statue in a football jersey of Arminia Bielefeld19.5.2025 13:25:14 CEST | Press release
Bielefeld. Schüco, the specialist in windows, doors and façades, has kitted out the tallest statue in Germany in the football jersey of DSC Arminia Bielefeld. It is the long-time sponsor's way of giving a gift to all the fans upon the team reaching the final of the German Cup. In fact, Arminia Bielefeld has reached the final of the German Cup for the first time in the club's 120-year history – and has done so as a third division team!
Sony Music Entertainment: The Whole World is Dancing to "Chicken Banana" TikTok's New Obsession – And Already One of 2025's Biggest Viral Hits15.5.2025 12:00:00 CEST | Press release
Listen to the song here: https://www.youtube.com/watch?v=ig7EKb6BrQk
Prof Dr Klemens Joos back as CEO of the EUTOP Group14.5.2025 13:27:53 CEST | Press release
Brussels - Prof Dr Klemens Joos (56) has been back at the helm of the EUTOP Group as CEO since 13 May 2025. The background to this is an ambitious growth strategy up to 2035 for the EUTOP Group, which he founded in 1990 while studying business administration at the Ludwig Maximilian University (LMU) in Munich. Just one year after its foundation, the company had a representative office in Brussels. Today, the EUTOP Group has subsidiaries or representative offices in the capitals of all major European Union member states in addition to Brussels. Prof Dr Klemens Joos is also an honorary professor of ‘Business Administration - Political Stakeholder Management’ at the Technical University of Munich (TUM). Enquiries & Contact: Press department EUTOP Group +49 89 323700-0 eutop@eutop.eu
New record achieved: NTT DATA Business Solutions exceeds the previous year’s top figures in terms of both revenue and results12.5.2025 11:12:03 CEST | Press release
2024/2025 saw a double-digit revenue growth of 14.7 percent to 1.85 billion euros EBIT in three digits for the first time at 109.9 million euros (+35.9%) Close to a 50 percent increase in cloud subscriptions Proportion of international business tops 60 percent mark Optimistic outlook despite global uncertainties
Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release
(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom